Veradermics Q3 net loss widens to $21 million
Bitget2026/11/10 12:31- Veradermics’ third-quarter 2026 net loss widened to $21 million from a year earlier.
- General and administrative expenses rose to $12.7 million, while research and development spending fell 11% to $16.08 million year over year.
- Cash, cash equivalents and marketable securities totaled $798.4 million at September 30, expected to fund operations into 2030.
- VDPHL01 delivered positive Phase 3 Study 304 results and positive 12-month Phase 2/3 Study 302 data in male pattern hair loss.
- Topline results from registration-directed Study 306 in female pattern hair loss remain on track for the first half of 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ampco-Pittsburgh Publishes Q3 2026 Earnings Call Transcript
Nvidia's newly appointed Chairman of the Board addresses all employees: The company's strength comes from its team, technology, and ecosystem.
In an email, NVIDIA's new Chairman of the Board Harvey Jones stated that the board takes its duty as guardian of this great company very seriously. The company's strength comes from our employees, leadership team, technological capabilities, and partner ecosystem. We will continue to drive business growth and lead the industry forward. Thank you all for your focus, professionalism, and dedication to NVIDIA.
Crypto prices
More
